| Bioactivity | Antitumor agent-151 (7k) is a significant HsClpP agonist and an antileukemia drug candidate. Antitumor agent-151 (7k) exhibits remarkably enhanced proteolytic activity of HsClpP (EC50 = 0.79 μM) and antitumor activity in vitro (IC50 = 0.038 μM). Antitumor agent-151 (7k) induces apoptosis[1]. |
| Invitro | Antitumor agent-151 (7k) 对 AML 细胞系有较强的抑制活性，其在 Molm13、U937、OCI-AML2、THP-1、HL60、KASSUMI、和 K562 细胞系中的 IC50 值分别为 30.1 ± 2.3、78.2 ± 3.1、39.2 ± 0.9、79.7 ± 0.3、40.5 ± 0.8、41.1 ± 1.7 和 131.8 ± 1.5 nM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Antitumor agent-151 相关抗体: |
| In Vivo | Antitumor agent-151 (7k，10 mg/kg，腹腔注射，携带Mv4-11急性髓系白血病细胞的雌性 BALB/c 裸鼠) 显示出强大的抗肿瘤效果[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| Formula | C22H20FN5O |
| Molar Mass | 389.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Xinrong Xiang, et al. Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity. J Med Chem. 2024 Apr 25;67(8):6769-6792. |